Lipitor Generic Suppression Antitrust Litigation
Court: United States District Court, District of New Jersey
Southeast Laborers Health and Welfare Fund v. Pfizer Inc., Case No.: 12-cv-02389
Leadership Position: Interim Co-Lead Class Counsel
Wexler Wallace LLP is serving as Interim Co-Lead Counsel for a proposed end-payor class in an action against Pfizer Inc. and Ranbaxy Pharmaceuticals Inc., among others, seeking damages and equitable relief for violations of antitrust and consumer protection laws in connection with Pfizer’s blockbuster cholesterol drug Lipitor. Plaintiffs allege that defendants fraudulently procured a patent covering Lipitor, engaged in sham litigation concerning that patent, and entered into a pay-for-delay deal in order to keep generic versions of the drug off of the market. As a result of these actions, market entry of a generic version of Lipitor was delayed for a number of years, forcing the proposed end-payor class to pay more for Lipitor and its generic equivalents than they would have in the absence of defendants’ anticompetitive conduct.
To view a copy of the complaint, click here.